2015
The Epi-TAF for Tenofovir Disoproxil Fumarate?
Walensky RP, Horn TH, Paltiel AD. The Epi-TAF for Tenofovir Disoproxil Fumarate? Clinical Infectious Diseases 2015, 62: 915-918. PMID: 26658300, DOI: 10.1093/cid/civ1000.Peer-Reviewed Original ResearchConceptsTenofovir disoproxil fumarateAverage wholesale priceDisoproxil fumarateBone mineral density lossHIV treatment regimenTenofovir/lamivudineImproved toxicity profileHuman immunodeficiency virusMineral density lossAntiretroviral therapyRenal injuryTenofovir alafenamideTreatment regimenImmunodeficiency virusEqual efficacyToxicity profileCost-effectiveness methodsDensity lossUS residentsAlafenamideRegimenLamivudineTherapyInjuryFumarate
2012
Antenatal lamivudine to reduce perinatal hepatitis B transmission: a cost-effectiveness analysis
Nayeri UA, Werner EF, Han CS, Pettker CM, Funai EF, Thung SF. Antenatal lamivudine to reduce perinatal hepatitis B transmission: a cost-effectiveness analysis. American Journal Of Obstetrics And Gynecology 2012, 207: 231.e1-231.e7. PMID: 22939730, DOI: 10.1016/j.ajog.2012.06.001.Peer-Reviewed Original ResearchConceptsChronic hepatitis BHepatitis BLamivudine administrationPerinatal transmissionThird trimesterPregnant womenPerinatal hepatitis B transmissionAdministration of lamivudineMaternal hepatitis BHepatitis B transmissionCost-effectiveness analysisDecision analysis modelExpectant managementLiver transplantPregnant patientsHepatocellular carcinomaB transmissionLamivudineCost-effective strategyAdministrationTrimesterPregnancyWomenPatientsCarcinomaA Randomized Controlled Trial of Highly Active Antiretroviral Therapy Versus Highly Active Antiretroviral Therapy and Chemotherapy in Therapy-Naive Patients With HIV-Associated Kaposi Sarcoma in South Africa
Mosam A, Shaik F, Uldrick TS, Esterhuizen T, Friedland GH, Scadden DT, Aboobaker J, Coovadia HM. A Randomized Controlled Trial of Highly Active Antiretroviral Therapy Versus Highly Active Antiretroviral Therapy and Chemotherapy in Therapy-Naive Patients With HIV-Associated Kaposi Sarcoma in South Africa. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2012, 60: 150-157. PMID: 22395672, PMCID: PMC3360837, DOI: 10.1097/qai.0b013e318251aedd.Peer-Reviewed Original ResearchConceptsHIV-KSKing Edward VIII HospitalSymptomatic visceral diseaseActive antiretroviral therapyOpen-label trialTreatment-naive patientsTertiary referral centerAdministration of chemotherapyHAART armUrgent chemotherapyAntiretroviral therapyReferral centerVisceral diseaseTreat analysisKaposi's sarcomaHAARTChemotherapySaharan AfricaOptimal approachHIVLamivudinePatientsSarcomaStavudineNevirapine
2010
SUPPORT: 48‐week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under‐represented, antiretroviral‐naïve patients
Kumar P, DeJesus E, Huhn G, Sloan L, Garcia F, Small C, Edelstein H, Felizarta F, Hao R, Ha B, Stancil B, Ross L, Oie K, Pappa K. SUPPORT: 48‐week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under‐represented, antiretroviral‐naïve patients. Journal Of The International AIDS Society 2010, 13: p7-p7. PMCID: PMC3113075, DOI: 10.1186/1758-2652-13-s4-p7.Peer-Reviewed Original Research
2000
Lactic Acidosis in the Setting of Antiretroviral Therapy for the Acquired Immunodeficiency Syndrome
Shaer A, Rastegar A. Lactic Acidosis in the Setting of Antiretroviral Therapy for the Acquired Immunodeficiency Syndrome. American Journal Of Nephrology 2000, 20: 332-338. PMID: 10970989, DOI: 10.1159/000013610.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyLactic acidosisAIDS patientsType B lactic acidosisAggressive supportive therapyContinuous venovenous hemodiafiltrationSerum lactate levelsAcquired Immunodeficiency SyndromeCases of patientsLiver failureFluid administrationImmunodeficiency syndromeSupportive therapySingle doseFatal disorderLactate levelsPatientsAcidosisMitochondrial myopathyTherapyEnglish literatureLamivudineStavudineSecond reportDichloroacetate
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply